Riptac therapeutics use a ‘hold-and-kill’ mechanism that is an innovative way to defeat cancer

Our RIPTAC therapeutics hold two proteins together: one that is tumor-specific and another that performs an essential function. The novel protein-protein interaction results in selective killing of the cancer cell.